ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

(d) Exhibits

* * *

Ultragenyx Pharmaceutical Inc. Exhibit
EX-99.1 2 d458520dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash Proposed Combination of Complementary Rare Disease Franchises Maximizes the Ability to Bring Needed New Therapies to Market Proposal Delivers Superior Value To Dimension’s Shareholders Relative to the REGENXBIO Transaction; Provides Dimension Shareholders with Immediate Cash Premium Value of Over 358% to Unaffected Share Price Ultragenyx to Host Conference Call Today at 10:30am ET NOVATO,…
To view the full exhibit click here

About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.